No Data
No Data
Harbin Pharmaceutical Group (600664.SH): Plans to achieve revenue of 16.461 billion yuan in 2024, a year-on-year growth of 6.5%.
According to the investment relations activity record disclosed by Harbin Pharmaceutical Group (600664.SH) on July 18th, the company plans to achieve a revenue of 16.461 billion yuan in 2024, a year-on-year growth of 6.5%; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses is 0.353 billion yuan, a year-on-year growth of 8.5%. At the same time, the company will control product production costs and various expenses and actively seek and cultivate new profit growth points. The above business goals do not represent the company's profit forecast for 2024, do not constitute the company's performance commitments to investors, and the company's actual operating conditions are subject to various internal and external factors.
Is Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Latest Stock Performance A Reflection Of Its Financial Health?
Most readers would already be aware that Harbin Pharmaceutical Group's (SHSE:600664) stock increased significantly by 14% over the past week. Given the company's impressive performance, we decided
Announcement of Half-Year Performance Forecast Increase for HAECO Group Co., Ltd. in 2024.
Harbin Pharmaceutical Group (600664.SH) has issued a profit forecast, with an expected net income of 0.312 to 0.375 billion yuan, a year-on-year increase of 71% to 105%.
Harbin Pharmaceutical Group (600664.SH) has released a performance forecast for the first half of 2024, with the company expecting...
Harbin Pharmaceutical Group (600664.SH) appointed Vice President Meng Xiaodong as the Chief Financial Officer.
Harbin Pharmaceutical Group (600664.SH) announced that the company's Board of Directors recently received Liu Bo, the company's Vice President and CFO...
Harbin Pharmaceutical Group (600664.SH): compound sulfamethoxazole tablets pass the consistency evaluation of generic drugs.
On June 7th, Gelunhui reported that Harbin Pharmaceutical Group Co., Ltd. (Stock Code: 600664.SH) announced that pharmaceutical manufacturing plant #6, a subsidiary of the company (referred to as Harbin #6) received the "Drug Supplementary Application Approval Notice" for compound sulfamethoxazole tablets issued by the State Drug Administration of China (SDA) [Notice No.: 2024B02460], and the quality and efficacy of the product have been deemed consistent with that of the reference listed drug. Compound sulfamethoxazole tablet is a compound preparation composed of sulfamethoxazole and methoxybenzoin. Each tablet contains 0.4g of active ingredient sulfamethoxazole and 80mg of methoxybenzoin. The main indications are infections caused by sensitive strains, including 1. Coliform
No Data